<- Go Home

Cybin Inc.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

Market Cap

$281.4M

Volume

134.3K

Cash and Equivalents

$154.3M

EBITDA

-$130.6M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

N/A

Profit Margin

N/A

52 Week High

$27.93

52 Week Low

$9.15

Dividend

N/A

Price / Book Value

1.10

Price / Earnings

-1.74

Price / Tangible Book Value

1.64

Enterprise Value

$127.2M

Enterprise Value / EBITDA

-0.98

Operating Income

-$130.8M

Return on Equity

-81.54%

Return on Assets

-51.09

Cash and Short Term Investments

$154.3M

Debt

$133.0K

Equity

$255.0M

Revenue

N/A

Unlevered FCF

-$51.3M

Sector

Pharmaceuticals

Category

N/A

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches